Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).

"Competing interests The authors declare the following relevant conflicts of interest. MJR has served as a paid consultant for Genentech and Sanofi-Aventis. HLM is on the board of directors of Vyant Bio, a Co-Founder of Clarified Precision Medicine and PGx Accelerator, and is a Scientific Advisor to VieCure and Illumina. JNP is a Scientific Advisor to VieCure and Clarified Precision Medicine."

"Funding The authors would like to acknowledge the following funding sources. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821, U10CA180882, and U24CA196171 (to the Alliance for Clinical Trials in Oncology), UG1CA233160, UG1CA233253, UG1CA233270, UG1CA233290, UG1CA233320, UG1CA233327, UG1CA233341, and UG1CA233373. https://acknowledgments.alliancefound.org. This study was also supported by the NIH Pharmacogenomics Research Network (PGRN) (GM61390), NIH/National Institute of General Medical Sciences (NIGMS) Pharmacogenomics of Anticancer Agents grant U01GM61393, NIH/National Institute of Nursing Research (NINR) P30NR014129; UG1CA233196, and U10CA180820 (ECOG-ACRIN). Also supported in part by funds from Genentech. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Cancer Institute. Open access funding provided by the Carolinas Consortium."